Research programme: HIV entry inhibitors - Ambrilia Biopharma

Drug Profile

Research programme: HIV entry inhibitors - Ambrilia Biopharma

Latest Information Update: 10 Jul 2013

Price : $50

At a glance

  • Originator Ambrilia Biopharma
  • Class Small molecules
  • Mechanism of Action HIV fusion inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 09 Jul 2013 Discontinued for HIV infections in Canada prior to 9 July 2013 (unspecified route)
  • 07 Jan 2011 Early research in HIV infections in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top